Adaptive Biotechnologies (ADPT) Misses Q1 Revs; Withdraws Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Adaptive Biotechnologies Reports First Quarter 2020 Financial Results
May 12, 2020 4:04 PM EDTSEATTLE, May 12, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Adaptive Biotechnologies) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2020.
Adaptives immune medicine platform was built to decode the specific immune response to any disease, which we are now applying in full force to COVID-19, said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. Importantly, we are able to do this while maintaining focus on our... More
